Voyager Transaction

Summary

On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH), announced that they have entered into a definitive business combination agreement.The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”

VISIT VOYAGER

View Management Presenttion